Species |
Human |
Protein Construction |
Expressed with additional N-terminal sequence (MFPAMPLSSLFVNGPRT).
LR3-IGF-I (Leu53-Ala118) Accession # P05019 |
|
Purity |
> 95% as analyzed by SDS-PAGE |
Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
Biological Activity |
ED50 < 10.0 ng/ml, measured by the dose-dependantproliferation of CHO cells, corresponding to a specific activity of > 1.0 × 105 units/mg. |
Expression System |
E. coli |
Apparent Molecular Weight |
~9.1 KDa, on SDS-PAGE under reducing conditions. |
Formulation |
Lyophilized after extensive dialysis against 50 mM acetic acid. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 10 mM HCl up to 1mg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
![LR<sup>3</sup>-IGF-I (Receptor Grade), Human LR<sup>3</sup>-IGF-I (Receptor Grade), Human](/product/documents/down?doc_name=Z03177_dose Dependent Proliferation.png&file=scm_files/productFile_notes/2024/01/19/48d9e28e-f3d4-4cd5-a53e-45285f081240.png)
ED50 < 10.0 ng/ml, measured by the dose dependent proliferation of CHO cells, corresponding to a specific activity of > 1.0 × 105 units/mg.
![LR<sup>3</sup>-IGF-I (Receptor Grade), Human LR<sup>3</sup>-IGF-I (Receptor Grade), Human](/product/documents/down?doc_name=Z03177_SDS-PAGE.png&file=scm_files/productFile_notes/2024/01/19/106c05b3-1d23-4b31-951e-7d7015c605ec.png)
Lane 1: 2 μg of LR3-IGF-I (Receptor Grade), Human, non-reducing (NR)
Lane 2: 2 μg of LR3-IGF-I (Receptor Grade), Human, reducing (R)
> 95% as analyzed by SDS-PAGE
Target Background |
IGF-1 is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-1 is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-2, which is also a major fetal growth factor. Human Long R3 Insulin-like Growth Factor-1 (rhLR3IGF-1) contains an 83 amino acid analog of human IGF-I. Compared to the complete human IGF-I sequence, an addition of the rhLR3IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3)and a13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of human Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs. |
Synonyms |
LR3 Insulin-like Growth Factor-I; LR3-IGF-I |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.